<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="30246">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02091817</url>
  </required_header>
  <id_info>
    <org_study_id>sor010712ctil</org_study_id>
    <secondary_id>ISF, 384/10</secondary_id>
    <nct_id>NCT02091817</nct_id>
  </id_info>
  <brief_title>The Effect of Oxytocin on Face Perception</brief_title>
  <official_title>The Behavioral and Neural Effects of Oxytocin on Face Perception in Congenital Prosopagnosia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Soroka University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ben-Gurion University of the Negev</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Soroka University Medical Center</source>
  <oversight_info>
    <authority>Israel: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether oxytocin affect face perception
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <primary_completion_date type="Anticipated">November 2014</primary_completion_date>
  <phase>Phase 0</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Memory performance</measure>
    <time_frame>24 hours after encoding</time_frame>
    <safety_issue>No</safety_issue>
    <description>At the day participants will administer the substance, they will view a set of faces, of which they will be tested about 24 hours later. The measures that will be tested are accuracy and eye movements.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mood measurement</measure>
    <time_frame>Before oxytocin/placebo uptake, and 45 min. after</time_frame>
    <safety_issue>No</safety_issue>
    <description>Participants will fill a PANAS mood questionnaire just before oxytocin/placebo uptake, and 45 minutes after oxytocin/placebo uptake, in order to monitor the effects of mood and fatigue of oxytocin/placebo.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Healthy</condition>
  <condition>Congenital Prosopagnosia</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Control group will be administered oxytocin and placebo, in a double-blind randomized order.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>congenital prosopagnosia (CP)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CP will be administered oxytocin and placebo in a double-blind randomized order.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin</intervention_name>
    <description>Intervention will be examined on control group, and on experimental group as well.</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>congenital prosopagnosia (CP)</arm_group_label>
    <other_name>syntocinon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be given to control group and experimental group as well.</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>congenital prosopagnosia (CP)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  normal or corrected to normal vision

        Exclusion Criteria:

          -  minors

          -  pregnancy (according to a pregnancy test taken by subjects prior to participation)

          -  a history of asthma or nasal polyps

          -  cardiac disorders

          -  hyponatremia

          -  acute or chronic renal insufficiency

          -  liver cirrhosis

          -  neurological disease

          -  other chronic disease

          -  dementia, or lack of judgment
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shelef Ilan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Soroka University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Galia Avidan, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ben-Gurion University of the Negev</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Soroka medical center</name>
      <address>
        <city>Beer Sheva</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weiss, M.A</last_name>
      <email>weissnil@post.bgu.ac.il</email>
    </contact>
    <investigator>
      <last_name>Ilan Shelef, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <reference>
    <citation>Avidan G, Behrmann M. Functional MRI reveals compromised neural integrity of the face processing network in congenital prosopagnosia. Curr Biol. 2009 Jul 14;19(13):1146-50. doi: 10.1016/j.cub.2009.04.060. Epub 2009 May 28.</citation>
    <PMID>19481456</PMID>
  </reference>
  <reference>
    <citation>Avidan G, Behrmann M. Implicit familiarity processing in congenital prosopagnosia. J Neuropsychol. 2008 Mar;2(Pt 1):141-64.</citation>
    <PMID>19334309</PMID>
  </reference>
  <reference>
    <citation>Avidan G, Hasson U, Malach R, Behrmann M. Detailed exploration of face-related processing in congenital prosopagnosia: 2. Functional neuroimaging findings. J Cogn Neurosci. 2005 Jul;17(7):1150-67.</citation>
    <PMID>16102242</PMID>
  </reference>
  <reference>
    <citation>Behrmann M, Avidan G, Marotta JJ, Kimchi R. Detailed exploration of face-related processing in congenital prosopagnosia: 1. Behavioral findings. J Cogn Neurosci. 2005 Jul;17(7):1130-49.</citation>
    <PMID>16102241</PMID>
  </reference>
  <reference>
    <citation>Hasson U, Avidan G, Deouell LY, Bentin S, Malach R. Face-selective activation in a congenital prosopagnosic subject. J Cogn Neurosci. 2003 Apr 1;15(3):419-31.</citation>
    <PMID>12729493</PMID>
  </reference>
  <reference>
    <citation>MacDonald E, Dadds MR, Brennan JL, Williams K, Levy F, Cauchi AJ. A review of safety, side-effects and subjective reactions to intranasal oxytocin in human research. Psychoneuroendocrinology. 2011 Sep;36(8):1114-26. doi: 10.1016/j.psyneuen.2011.02.015. Epub 2011 Mar 23. Review.</citation>
    <PMID>21429671</PMID>
  </reference>
  <reference>
    <citation>Avidan G, Tanzer M, Hadj-Bouziane F, Liu N, Ungerleider LG, Behrmann M. Selective Dissociation Between Core and Extended Regions of the Face Processing Network in Congenital Prosopagnosia. Cereb Cortex. 2013 Jan 31. [Epub ahead of print]</citation>
    <PMID>23377287</PMID>
  </reference>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 17, 2014</lastchanged_date>
  <firstreceived_date>January 26, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Soroka University Medical Center</investigator_affiliation>
    <investigator_full_name>Ilan Shelef</investigator_full_name>
    <investigator_title>Head of medical imaging at Soroka University Medical Center</investigator_title>
  </responsible_party>
  <keyword>oxytocin</keyword>
  <keyword>face</keyword>
  <keyword>memory</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prosopagnosia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
